Isis to restart ISIS 2302 for Crohn's

ISIP said it will restart development of its antisense ICAM-1 inhibitor, ISIS 2302, to treat Crohn's disease. The decision follows additional analysis of a Phase II/III trial showing 38 percent of pat...